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Objective—Increased caffeine intake is associated with a lower risk of Parkinson’s disease (PD) 
and is neuroprotective in mouse models of PD. However, in a prior study, an exploratory analysis 
showed that, in patients taking creatine, caffeine intake was associated with a faster rate of 
progression. In the current study we investigated the association of caffeine with the rate of 
progression of PD and the interaction of this association with creatine intake.
Methods—Data were analyzed from a large Phase 3 placebo-controlled clinical study of creatine 
as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 
movement disorders centers across the United States and Canada. A total of 1,741 PD subjects 
participated in the primary clinical study, and caffeine intake data were available for 1,549 of 
these subjects. The association of caffeine intake with rate of progression of PD as measured by 
the change in the total Unified Parkinson Disease Rating Scale (UPDRS) score, and the interaction 
of this association with creatine intake, were assessed.
Results—Caffeine intake was not associated with the rate of progression of PD in the main 
analysis, but higher caffeine intake was associated with significantly faster progression among 
subjects taking creatine.
Conclusions—This is the largest and longest study conducted to date that addresses the 
association of caffeine with the rate of progression of PD. These data indicate a potentially 
deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.
INTRODUCTION
Caffeine has a dose-depended inverse association with the risk of developing Parkinson’s 
disease (PD)(1, 2)Caffeine is an antagonist at adenosine A2a receptors, although a recent 
study suggested that it may act as an A2a inverse agonist(3). Both caffeine and other more 
specific A2a receptor antagonists are neuroprotective in toxin-induced PD animal models(4). 
Furthermore, mice lacking the A2a receptor are protected against dopaminergic 
neurodegeneration induced by mutant α-synuclein(5). These data have led to the hypothesis 
that caffeine may have a neuroprotective effect in PD. As a preliminary test of this 
hypothesis, we previously analyzed data from 2 Phase 2 futility-design clinical studies of 
potential disease-modifying therapies in PD. Arms in the studies included creatine, 
minocycline and placebo in one study (FS1)(6); and coenzyme Q10, GPI-1485 (an 
immunophilin ligand) and placebo in the other(FS2)(7). A caffeine intake questionnaire was 
completed by participating subjects. Unexpectedly, among subjects randomized to creatine, 
increasing levels of caffeine intake were associated with significantly faster progression of 
PD as measured by the change in the total UPDRS score, whereas there was no consistent 
association of caffeine with progression in other treatment groups(8). We sought to replicate 
and extend this surprising but potentially important observation by analyzing the association 
of caffeine intake with the rate of progression of PD as a substudy of a large multicenter 
double-blind, placebo-controlled Phase 3 clinical study of creatine as a potentially disease-
modifying therapy in PD, the “Large Long Term Study” (LS1)(9).
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METHODS
Study subjects and the LS1 study
A total of 1,741 early PD subjects (diagnosed within 5 years) already treated with 
dopaminergic therapy were enrolled in LS1 and randomized 1:1 to creatine 10 grams per 
day or placebo. Subjects were recruited from 45 sites in the US and Canada. All subjects 
were within 5 years from diagnosis and were receiving dopaminergic therapy (levodopa or a 
dopamine agonist) for at least 90 days but no more than 2 years at the time of recruitment 
into the study. This study was sponsored by the National Institute of Neurological Disorders 
and Stroke (NINDS). Details of the study design and characteristics of participants have 
been published elsewhere(9, 10). The goal was to follow all subjects for a minimum of 5 
years; however, a preplanned interim analysis conducted when half of the subjects had 
reached the 5-year time point suggested that creatine was unlikely to meet the pre-specified 
threshold for significant slowing of clinical disease progression, and the study was 
terminated early. All study procedures were approved by institutional review boards at each 
participating site.
Caffeine questionnaire
A total of 1,549 subjects completed a caffeine intake questionnaire that had been used 
previously in the Futility Study (FS)1 study(8). This questionnaire focused primarily on 
intake of caffeinated beverages during the prior week. The majority of subjects who 
completed the questionnaire did so at the 18-month time point of the study. In this analysis 
we did not take into account those who did not complete a questionnaire, but data comparing 
characteristics of those who completed or did not complete the caffeine questionnaire are 
presented.
Statistical methods
The primary outcome measure was the total Unified Parkinson’s Disease Rating Scale 
(UPDRS) score during all years of follow-up, with baseline UPDRS included as a covariate. 
For all analyses (baseline and follow-up) we defined “total UPDRS” as the sum of scores for 
a participant for UPDRS parts I-III. The UPDRS was selected a priori for this analysis as 
this measure was used in our prior study based on data from the FS1 and FS2 studies(8). We 
sought to determine if we could replicate the results of that prior study in the current 
analysis of data from the larger and longer duration LS1. The distribution of daily caffeine 
consumption was zero-inflated and highly skewed to the right. A log and square root 
transformation did not lead to normally distributed data due to the high percentage of zero 
values. Therefore, caffeine was analyzed as a categorical variable, with subjects split into 
high and low caffeine intake groups. The low caffeine group was defined as subjects with 
daily caffeine intake less than or equal to 300 mg. The high caffeine group had caffeine 
intakes greater than 300 mg per day. This cutoff of 300mg has been used in previous studies 
Ascherio, 2001 #645;Fernandez-Duenas, 2014 #3085;Ross, 2000 #644;Schwarzschild, 2003 
#3082} of health-related impacts of caffeine consumption.
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Baseline characteristics were compared for the low (N=1,288) and high (N=261) caffeine 
groups. P-values from Wilcoxon and Chi-square tests were obtained for continuous and 
binary variables respectively.
To assess the effect of caffeine while adjusting for other covariates and interactions, a mixed 
model was used with site as random effect. The response variable was the annual total 
UPDRS score from year 1 to 5. The mixed model used all available longitudinal annual 
measurements of UPDRS, assuming the correlation structure of multiple measurements 
within each individual to be Heterogeneous Auto Regression One (ARH1). The Auto 
Regression (AR1) structure assumes the correlation of yearly UPDRS is mainly related to 
measurements in neighboring years and the relationships decrease as the time between 
measurements increase. The heterogeneous structure relaxed the variance assumption for 
each measurement and allows a different variance at each time point.
Models were fit by SAS PROC MIXED using REML method. Fixed effect parameters were 
estimated for every model. REML in PROC MIXED accommodates data that are missing at 
random. Missing data in our sample were mostly due to loss of follow-up, drop-outs or 
deaths. Loss of follow-up here refers to loss due to early trial closure; drop-outs appeared to 
be unrelated to caffeine and thus were considered missing at random as well. Death could be 
considered missing at random only if the reason for death was not related to caffeine 
consumption. There was no association of caffeine intake with cardiac death in this data set, 
a cause of death that in theory might have been related to caffeine, so death also was 
considered missing at random.
We fit the basic model using caffeine category (high versus low) along with other variables 
of clinical interest, which included treatment group, age at enrollment, years since 
enrollment (year), baseline UPDRS score, and gender as main effects. Treatment by caffeine 
interaction, treatment by gender interaction, and year interactions with treatment, caffeine, 
age, gender and baseline UPDRS, as well as the three way interactions of 
treatment*caffeine*year, treatment*gender*year, caffeine*gender*year were tested for their 
significance by interaction plots and Wald Test p values. The final basic model included 
significant main effects at the 0.05 level and significant interactions at the 0.1 level.
Next we assessed the confounding and modifying effect of covariates that might associate 
with caffeine or disease progression. First, the pairwise correlation was computed between 
continuous variables. In order to avoid multi-colinearity, variables that were highly 
correlated were not both kept in the model. Each covariate was added to the basic model to 
test its influence on disease progression. Their interaction with caffeine also was tested by 
two-way and three-way interactions with time. Wald Test with p values less than 0.05 for 
main effects and 0.1 for interaction terms were used to select variables for the final model. 
Main effects remained in the model if any interactions including this main effect were 
significant. Final model diagnostics checked the normality of the residual plot and the 
pattern of residual versus predictors. If a significant interaction of treatment (creatine versus 
placebo) by caffeine group was detected, separate models for treatment groups were built to 
assess the effect of caffeine in the different groups.
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RESULTS
Baseline characteristics of the 1,549 subjects who completed the caffeine questionnaire and 
for the 192 subjects who did not are shown in Table 1. Most baseline characteristics were 
not significantly different between these 2 groups. Subjects who did not provide caffeine 
intake data had significantly higher baseline Beck Depression Inventory (BDI) scores, 
UDPRS scores and levodopa dose equivalents, suggesting that depressive symptoms or 
more severe PD symptoms may have reduced the chances of completing the caffeine 
questionnaire.
The distribution of caffeine intake is shown in Figure 1. Table 2 compares baseline 
characteristics for subjects in the high and low caffeine groups. Uric acid levels were 
compared due to the association of uric acid levels with rate of progression of PD(11), and 
to reports that high caffeine intake may be associated with lower uric acid levels(12). 
Median uric acid levels and median body mass index (BMI) were significantly higher in 
subjects in the high caffeine group, whereas days since diagnosis at the time of study entry 
was lower in the high caffeine group. A significantly lower percentage of female subjects 
was present in the high versus low caffeine group.
In the final model, there was a significant 3-way interaction between treatment group 
(creatine versus placebo), caffeine category (high versus low) and years since enrollment in 
assessing the association with total UPDRS score (i.e. rate of progression). Therefore, the 
placebo and creatine groups were analyzed separately. For the placebo group, caffeine and 
rate of progression did not interact. In contrast, there was a significant interaction between 
caffeine and rate of progression for the creatine group, with high caffeine intake being 
associated with more rapid progression (Figure 2 and Table 3; p = 0.002). Uric acid was not 
statistically significant in either model (p-values >0.1), and so was not included in the model 
based on our model selection criteria.
The lack of an interaction between caffeine and rate of progression in the placebo group is 
consistent with a similar analysis in a previously published study(8). However, it remains 
possible that even modest levels of caffeine below the 300mg cutoff used for our primary 
analysis might be associated with slowing of clinical progression of PD, which would limit 
our ability to detect an association of caffeine with rate of progression using the 300mg 
threshold. To address this possibility, we conducted an additional post-hoc analysis of 
caffeine and rate of progression comparing subjects with very low caffeine intake (<25mg/
day; n=662) to those in the high caffeine group (>300mg/day; n=261), and again there was a 
lack of a significant interaction in the placebo group.
An interesting possibility raised by these results is that the association of high caffeine 
intake with a faster rate of progression among subjects taking creatine may have masked a 
protective effect of creatine among subjects with low levels of caffeine intake. However, 
subgroup analyses restricted to subjects in the low caffeine group (<300mg/day; n=1,288) or 
the very low caffeine group (<25mg/day; n=662) revealed no significant associations of 
treatment (creatine versus placebo) and rate of progression of PD.
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DISCUSSION
Epidemiological data indicate a dose-dependent association of caffeine intake with the risk 
of PD(1, 2). Furthermore, caffeine is neuroprotective in animal models of PD(4), raising the 
possibility that caffeine also may have neuroprotective effects in PD patients. Therefore, we 
predicted that high caffeine intake would be associated with slower progression of PD. 
Contrary to this prediction, we found that among patients randomized to take creatine, 
higher caffeine intake was associated with a significantly faster rate of progression of PD, 
whereas there was no significant association detected for caffeine with the rate of 
progression among placebo subjects.
In a prior study of 2 smaller clinical cohorts, we similarly found no association of caffeine 
intake with the rate of progression of PD(8) over 12 months. This prior study also 
unexpectedly identified a significant association of caffeine with a faster rate of progression 
among subjects taking creatine, but this finding was not considered to be definitive due to 
the small number of subjects in that study (n = 64 subjects on creatine), the lack of an a 
priori prediction of this result, and a result of borderline significance. In contrast, the current 
study included clinical progression data for up to 5 years from 1,549 subjects. Furthermore, 
based on the results of the prior study, for the current study we specifically hypothesized a 
priori that higher caffeine intake would be associated with faster progression among subjects 
taking creatine. Indeed, we confirmed this result (p = 0.002), suggesting a deleterious 
interaction between caffeine and creatine with respect to the rate of clinical progression of 
PD. Although data on the frequency of combined use of creatine and caffeine in the general 
population are not available, caffeine use is common, with 17% of PD subjects in the LS1 
study having intakes greater than 300mg/day. Creatine supplements also are common among 
certain populations, with one study suggesting that 50% of high school senior football 
players using creatine supplements(13). However, the prevalence of creatine use in the 
general PD population is unknown. The current study was restricted to PD patients and so it 
remains unknown if there may be a deleterious interaction between creatine and caffeine use 
in people who do not have PD or in a younger population.
The LS1 trial of creatine ended early for futility based on a pre-planned interim analysis. 
Our observation of a faster rate of progression among subjects with high levels of caffeine 
intake raises the interesting possibility that creatine may actually have had a beneficial effect 
among subjects with lower levels of caffeine intake, but this effect was negated by the 
deleterious effect among subjects with high levels of caffeine intake. However, no 
significant association of creatine with rate of progression of PD even was detected when 
considering only those subjects in the low caffeine group (<300mg/day) or only those 
subjects with very low caffeine intake (<25mg/day).
Recent data have suggested that caffeine may have a symptomatic benefit in PD(14). We 
observed a similar mean levodopa equivalent dose at baseline among subjects in the low and 
high caffeine groups, and a nonsignificant trend towards lower baseline UPDRS scores in 
the high caffeine group. However, because this study was not randomized with respect to 
caffeine intake, the lower baseline UPDRS scores do not necessarily imply a symptomatic 
benefit from caffeine. In any case, a symptomatic effect of caffeine on PD symptoms should 
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not complicate our analysis of the association of caffeine intake with progression of PD 
unless either the level of caffeine intake changes during the study, or if the magnitude of the 
symptomatic benefit of caffeine changes as the disease progresses.
The potential mechanism by which caffeine and creatine may negatively interact with 
respect to the rate of progression of PD is not addressed in the current study. A prior study 
suggested that caffeine completely negates the effects of creatine on muscle contraction(15, 
16), potentially by counteracting the creatine associated facilitation of calcium uptake by the 
sarcoplasmic reticulum(16). It is interesting to note that high caffeine intake was associated 
with a mild but significant increase in uric acid levels (Table 2). This contrasts with prior 
reports of an association of caffeine with lower serum uric acid levels(17), and suggests that 
the relationship between caffeine intake and uric acid level may be different in PD patients 
compared to the general population. Uric acid is an antioxidant and high uric acid levels 
have been associated with a lower risk of PD and with a slower rate of progression of 
PD(18). However, despite the higher uric acid levels in the high caffeine group, we did not 
detect an association of high caffeine use with a slower rate of progression of PD.
This study has several strengths, including a large population of PD patients with detailed 
clinical assessments by movement disorders specialists over several years, as well as 
availability of data on caffeine intake for a majority of the subjects. There also are 
limitations. Caffeine data were collected at only one time point during the study, and this 
was 18 months after baseline. Therefore, our analyses could not account for potential 
changes in levels of caffeine intake over the course of the study. In our previously published 
study a repeat caffeine questionnaire was administered after 1 year, and this demonstrated 
that the level of caffeine intake was relatively stable (changed by less than 25%) in ~90% of 
subjects(8). However, the percentage of subjects with changes in caffeine intake likely is 
greater in the current study due to its longer duration. Not all participants provided caffeine 
data, although baseline differences between those who provided data and those who did not 
were minimal. The most important drawback is that subjects were not randomized or 
blinded with respect to caffeine intake. It is possible that other factors that are associated 
with caffeine use could influence these results. Relating to this point, data on smoking were 
not collected for the LS1 subjects. There is an association with caffeine and tobacco use(19). 
This raises the possibility that the associations with caffeine reported in this study may 
reflect an influence of tobacco use. However, the current results replicate our prior report 
that caffeine use is inversely associated with rate of clinical progression of PD in subjects 
taking creatine, and results in the prior study remained significant after adjusting for 
smoking(8). Similarly, in a study by Hamza et al identifying GRIN2A genotype as a 
modifier of the influence of caffeine on the risk of PD, the results were similar before and 
after adjusting for smoking(4). Furthermore, the frequency of smoking is low in PD 
patients(19), and so this issue is likely to be relevant to only a small percentage of LS1 
subjects. A case control study of over 500 PD patients and a similar number of controls at 
movement disorders centers in the US revealed that only 3.6% of PD subjects smoked 
cigarettes and also had significant caffeine intake(20)(Tanner et al., unpublished data).
Simon et al. Page 7
Clin Neuropharmacol. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
An additional possible limitation is the retrospective self-reported nature of the caffeine 
questionnaire, although studies on caffeine intake quantification have documented the 
validity of self-report methods(21).
In conclusion, these data show no association of caffeine with the rate of clinical progression 
of PD except in the group of participants taking creatine where progression was increased. 
This study was not randomized or blinded with respect to caffeine intake. For this reason, 
and based on the strength of epidemiological and preclinical data suggesting that caffeine 
may have neuroprotective effects in PD, further study of the potential neuroprotective 
effects of caffeine and other A2a receptor antagonists remains warranted. Given the lack of 
any benefits of creatine for PD patients in the LS1 study, as well as the possibility of a 
deleterious effect when combined with caffeine, it remains prudent to recommend against 
creatine supplementation for PD patients.
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Figure 1. Distribution of daily caffeine intake
Distribution of daily caffeine intake among the 1,549 subjects for whom caffeine intake data 
were available. The mean intake was 134.8mg per day
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Figure 2. Caffeine and total UPDRS
2a) Loess plot for total UPDRS over year by caffeine categories. The y axis used the fitted 
value of total UPDRS from the creatine subgroup model (Table 3). The smoothing 
parameters are automatically selected by SAS PROC SGPLOT.
2b) Interaction plot of treatment by caffeine categories over total UPDRS. The y axis is the 
fitted UPDRS from the final model for the whole population. Smoothing parameter is 0.3 in 
SAS PROC SGPLOT.
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Table1
Baseline characteristics of those who completed the caffeine questionnaire to those who did not.
Caffeine data
available
N=1549
Caffeine data
NOT available
N=192
p-value1
Levodopa Equiv. Median 300.0 389.5 <0.001**
Dose at Baseline SD 242.31 255.49
IQ range* 225.0 275.0
Beck Depression Median 6.0 6.5 <0.007**
Index SD 5.40 6.49
IQ range 6.0 9.0
Uric Acid Median 5.0 5.1 0.51
SD 1.34 1.38
IQ range 1.8 1.6
Body Mass Index Median 27.0 27.7 0.12
SD 7.07 5.64
IQ range 5.9 5.5
Age at Enrollment Median 62.0 64.0 0.15
SD 9.39 11.42
IQ range 12.0 14.0
Days since Diagnosis Median 483.0 470.5 0.78
SD 401.0 347.36
IQ range 496.0 482.5
UPDRS Baseline Median 24.0 29.0 <0.0001***
SD 11.08 13.10
IQ range 15.0 17.5
Female Freq 553 65 0.61
% 35.70 33.85
Treatment(Creatine) Freq 776 98 0.80
% 50.10 51.04
1Continuous variables are tested using Wilcoxon Two-Sample Test; Binary variables are tested using Chi-square test.
*
IQ range is interquartile range.
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Table 2
Baseline characteristics of subjects in the low (≤300mg) and high (>300mg) caffeine intake groups
Low Caffeine
N=1288
High Caffeine
N=261 p-value
2
Levodopa Equiv. Median 300.0 300.0 0.38
Dose at Baseline SD 236.73 267.74
IQ range* 225 300.0
Beck Depression Median 6.0 5.0 0.12
Index SD 5.45 5.11
IQ range 6.0 6.0
Uric Acid Median 5.0 5.3 0.04**
SD 1.34 1.34
IQ range 1.9 1.8
Body Mass Index Median 26.7 27.8 <0.0001***
SD 7.37 5.31
IQ range 5.9 5.3
Age at Enrollment Median 62.0 61.0 0.23
SD 9.42 9.24
IQ range 13.0 13.0
Days since Diagnosis Median 493.0 412.0 0.003**
SD 404.42 379.06
IQ range 492 480
UPDRS Baseline Median 25.0 22.5 <0.07*
SD 11.17 10.55
IQ range 15.0 15.0
Female Freq 490 63 <0.0001***
% 38.04 24.14
Treatment(Creatine) Freq 647 129 0.81
% 50.23 49.43
2Continuous variables are tested using Wilcoxon Two-Sample Test; Binary variables are tested using Chi-square test.
*
IQ range is interquartile range.
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Table 3
Final models for the subgroup of subjects randomized to creatine (N=765) and to placebo (N=770)
Effect for Creatine Sub-Group Estimate Standard Error DF t Value Pr > |t|
Intercept 3.54 2.84 49 1.25 0.22
Baseline UPDRS 0.76 0.03 3028 24.91 <.0001***
+Years since enrollment ---- ---- ---- ----
+Caffeine category ---- ---- ---- ----
Gender −1.40 0.67 3028 −2.08 0.04**
Age 0.01 0.04 3028 0.24 0.814
Beck Depression Inventory (BDI) 0.24 0.06 3028 3.91 <.0001***
Years since enrollment*Age 0.07 0.02 3028 4.40 <.0001***
Years since enrollment*Caffeine category 1.29 0.42 3028 3.07 0.002**
Effect for Placebo Sub-Group
Intercept 9.81 2.80 48 3.50 0.001
Baseline UPDRS 0.75 0.03 3067 25.58 <.0001***
+Years since enrollment ---- ---- ---- ---- <.0001***
Caffeine Category −0.21 0.73 3067 −0.29 0.77
Gender −2.20 0.58 3067 −3.80 0.0001***
+Age ---- ---- ---- ---- 0.06*
Beck Depression Inventory (BDI) 0.2158 0.05522 3067 3.91 <.0001***
Years since enrollment*Age 0.1110 0.01615 3067 6.87 <.0001***
+Where there is an interaction the main effect is difficult to interpret and is not reported.
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